Ovid Therapeutics Inc. Balance Sheet
OVID|4 years of annual SEC 10-K data (FY2022-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 4 fiscal years. All figures from audited SEC 10-K filings.
Ovid Therapeutics Inc. had $151M in total assets and $68M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.61 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash & Equivalents | $13.2M | $26.3M | $27.0M | $44.9M |
| Current Assets | $74.4M | $55.9M | $109.6M | $131.4M |
| PP&E (Net) | $252.0K | $433.0K | $768.8K | $1.1M |
| Total Assets | $150.9M | $92.2M | $144.0M | $155.3M |
| Current Liabilities | $8.3M | $10.5M | $11.5M | $7.0M |
| Shareholders' Equity | $68.2M | $87.8M | $132.3M | $179.7M |